Full Press Release Details
Therapeutics Announces ADS Ratio Change
FL and LONDON - March 17, 2026 - Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing
antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of
its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio
of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.
ratio change is intended to enable Akari to maintain compliance with the Nasdaq minimum bid price requirement for continued listing.
On the effective date, each ADS holder will be required to exchange every forty ADSs for one new ADS. Deutsche Bank, the depositary bank,
will arrange for the exchange of the current ADSs for the new ADSs. There is no change to Akari's underlying ordinary shares, and
Akari's ADSs will continue to trade on the NASDAQ Capital Market under the symbol AKTX.
fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will
be aggregated and sold and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and
expenses) will be distributed to the applicable ADS holders by Deutsche Bank.
can give no assurances of the performance of the ADS price following the ratio change.
Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1,
which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and
optimize them based on the desired application to any antigen target of interest. Akari's lead candidate, AKTX-101, targets the
Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with
minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel
payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown
in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust
and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs
with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated
prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to
be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated
IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing
AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen
broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari's proprietary PH1 spliceosome-modulating
payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Note Regarding Forward-Looking Statements
press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties
relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking
statements. Words such as "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict," "project,"
"potential," "continue," "future," "opportunity" "will likely result," "target,"
variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements,
although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but
are not limited to, express or implied statements regarding statements related to the ratio change and expected effective date of the
ratio change. These statements are based on the Company's current plans, estimates and projections. By their very nature, forward-looking
statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described
in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors
that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company's
need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses,
earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management
strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic
conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or
development of the Company's programs or product candidates; risks related to any loss of the Company's patents or other
intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company's product
candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of
product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research
and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead
to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization,
market acceptance, and commercial success of the Company's product candidates; risks related to competition for the Company's
product candidates; and the Company's ability to successfully develop or commercialize its product candidates. While the foregoing
list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential
risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this
press release except as required by law.